Source-grounded facts extracted from DiaMedica Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DiaMedica Therapeutics Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ende.
“Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025.”
DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2025.
“On March 30, 2026, DiaMedica Therapeutics Inc. (the "Company") announced its consolidated financial results for the year ended December 31, 2025.”
Richard Pilnik departed as Director at DiaMedica Therapeutics Inc..
“On February 28, 2025, Richard Pilnik, who has been a member of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), for over 15 years, informed the Company of his decision to retire and not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”).”
Daniel J. O'Connor was appointed as Director at DiaMedica Therapeutics Inc..
“On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.”
Rebekah de Vitry Fries changed role as other_named_officer at DiaMedica Therapeutics Inc..
“Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.”
Julie VanOrsdel Daves resigned as Senior Vice President, Clinical Development Operations at DiaMedica Therapeutics Inc..
“Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.”
DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2023.
“On March 19, 2024, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.